{"gene":"UBD","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":1999,"finding":"FAT10 noncovalently associates with MAD2, a spindle-assembly checkpoint protein, as determined by yeast two-hybrid screening and immunoprecipitation studies.","method":"Yeast two-hybrid screen, co-immunoprecipitation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and yeast two-hybrid, single lab, two orthogonal methods","pmids":["10200259"],"is_preprint":false},{"year":2001,"finding":"FAT10 forms covalent conjugates with cellular proteins via its C-terminal diglycine motif (isopeptide bond), and expression of wild-type but not diglycine-mutant FAT10 induces caspase-dependent apoptosis in mouse fibroblasts.","method":"Tetracycline-repressible expression system, annexin V staining, DNA fragmentation assay, diglycine mutant","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional mutagenesis with multiple apoptosis readouts, single lab","pmids":["11445583"],"is_preprint":false},{"year":2004,"finding":"NUB1L (NEDD8 ultimate buster-1L) interacts noncovalently with FAT10 more strongly than with NEDD8, and NUB1L coexpression accelerates FAT10 degradation approximately 8-fold, likely by linking FAT10 to the proteasome via RPN10.","method":"Yeast two-hybrid screen, co-immunoprecipitation, GST pull-down, cycloheximide chase degradation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, GST pulldown, functional degradation assay, multiple orthogonal methods in single rigorous study","pmids":["14757770"],"is_preprint":false},{"year":2005,"finding":"FAT10 and its conjugates are rapidly degraded by the proteasome in a ubiquitin-independent manner; mutation of all lysines on FAT10 or expression in ubiquitylation-deficient cells does not impair FAT10 degradation; N-terminal fusion of FAT10 to long-lived proteins accelerates their degradation as potently as ubiquitin fusion.","method":"Cycloheximide chase, proteasome inhibitor treatment, ubiquitylation-deficient cell lines, FAT10-GFP fusion protein degradation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including mutant cells and fusion protein assays, rigorous controls","pmids":["15831455"],"is_preprint":false},{"year":2006,"finding":"FAT10 overexpression reduces kinetochore localization of MAD2 during prometaphase, abbreviates mitotic phase, and causes increased chromosomal instability (multinucleation, variable chromosome number) in cells.","method":"Immunofluorescence, flow cytometry, double-thymidine synchronization, nocodazole treatment, chromosome counting","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct imaging of kinetochore localization with functional chromosome instability readout, single lab","pmids":["16495226"],"is_preprint":false},{"year":2006,"finding":"p53 negatively regulates FAT10 expression by binding to a p53-binding site in the FAT10 promoter (5'UTR region), as shown by promoter-luciferase assays and chromatin immunoprecipitation.","method":"Promoter-luciferase assay, siRNA knockdown, ChIP, p53 transfection into p53-null cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and functional luciferase assays, multiple approaches, single lab","pmids":["16501612"],"is_preprint":false},{"year":2007,"finding":"UBA6 (E1-L2) is the E1-activating enzyme for FAT10; it forms a thioester with FAT10 in vitro requiring UBA6's active-site cysteine and FAT10's C-terminal diglycine motif; RNAi silencing of UBA6 blocks FAT10 conjugate formation in cells.","method":"In vitro thioester formation assay, active-site cysteine mutagenesis, RNAi knockdown, endogenous co-immunoprecipitation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis plus cellular RNAi validation, multiple orthogonal methods","pmids":["17889673"],"is_preprint":false},{"year":2008,"finding":"FAT10 interacts with HDAC6 via the HDAC6 BUZ domain and first catalytic domain (catalytic activity not required); under proteasome impairment, FAT10 and FAT10 conjugates localize to aggresomes in a microtubule-dependent manner, and aggresome formation is reduced in HDAC6-deficient fibroblasts.","method":"Co-immunoprecipitation, domain mapping, live-cell imaging, microtubule depolymerization, HDAC6-deficient fibroblasts","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional genetic knockout, live-cell localization, multiple orthogonal methods","pmids":["19033385"],"is_preprint":false},{"year":2009,"finding":"FAT10-mediated degradation of FAT10-DHFR by purified 26S proteasome in vitro is ubiquitin-independent but strictly requires NUB1L; NUB1L knockdown attenuates FAT10-DHFR degradation in intact cells.","method":"In vitro proteasome degradation assay with purified components, siRNA knockdown, cycloheximide chase","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified 26S proteasome, confirmed in cells by knockdown, rigorous controls","pmids":["19166848"],"is_preprint":false},{"year":2009,"finding":"FAT10 deficiency in renal tubular epithelial cells impairs TNF-α-induced IκBα degradation and p65 nuclear translocation, and reduces LMP2 expression; re-expression of FAT10 restores NF-κB activation, and LMP2 transfection rescues IκBα degradation in FAT10-deficient cells.","method":"FAT10-/- mouse-derived cells, lentiviral transduction, Western blot, nuclear fractionation, NF-κB reporter assay","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout cells with rescue experiment, multiple pathway readouts, single lab","pmids":["19959714"],"is_preprint":false},{"year":2010,"finding":"USE1 (UBA6-specific E2 enzyme) is both the first E2 conjugating enzyme and the first identified substrate in the FAT10 pathway; activated FAT10 is transferred from UBA6 onto USE1 in vitro; USE1 auto-FAT10ylates itself in cis but not in trans; siRNA-mediated USE1 knockdown strongly reduces FAT10 conjugate formation.","method":"In vitro FAT10 transfer assay, co-immunoprecipitation, siRNA knockdown, cis vs trans auto-FAT10ylation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, cellular validation by knockdown, mechanistic dissection of cis vs trans activity, multiple methods","pmids":["20975683"],"is_preprint":false},{"year":2011,"finding":"TNF-α induces FAT10 expression through TNFR1 and NF-κB, and FAT10 mediates TNF-α-induced abbreviated mitotic phase, reduction of MAD2 kinetochore localization, and chromosomal instability; shRNA against FAT10 reverses these effects.","method":"shRNA knockdown, flow cytometry, immunofluorescence, chromosome counting, TNF-α treatment with receptor blocking","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA rescue experiments with specific pathway readouts, single lab, multiple methods","pmids":["22025632"],"is_preprint":false},{"year":2011,"finding":"FAT10 is covalently attached (via C-terminal glycine) to huntingtin and other polyglutamine proteins; FAT10 preferentially binds huntingtin with short polyQ chains; FAT10 knockdown enhances aggregation of ataxin-1, ataxin-3, and DRPLA proteins.","method":"Co-immunoprecipitation, FAT10 knockdown, aggregation assay in Huntington disease cell model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with knockdown validation, multiple polyQ substrates tested, single lab","pmids":["21757738"],"is_preprint":false},{"year":2011,"finding":"FAT10 degradation requires ubiquitination: degradation is inhibited in cells expressing a non-polymerizable ubiquitin mutant and in cells with a thermolabile ubiquitin-activating E1 enzyme; FAT10 as a degradation signal for stable proteins also requires ubiquitination for proteasomal targeting.","method":"Ubiquitin mutant expression, thermolabile E1 mutant cell line, cycloheximide chase","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent genetic approaches showing ubiquitin dependence, single lab; note this contradicts Hipp et al. 2005 ubiquitin-independence finding","pmids":["22072791"],"is_preprint":false},{"year":2012,"finding":"FAT10 and NUB1L bind to the VWA domain of 26S proteasome subunit Rpn10 (hRpn10/S5a) to enable FAT10-mediated proteolysis; NUB1L additionally binds Rpn1; depletion of hRpn10 causes accumulation of FAT10-conjugates in human cells; human Rpn10 with VWA domain alone functionally reconstitutes Rpn10-deficient yeast for FAT10 degradation.","method":"Co-immunoprecipitation, yeast complementation, siRNA knockdown, domain deletion mapping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including yeast reconstitution, domain mapping, human cell depletion, cross-species validation","pmids":["22434192"],"is_preprint":false},{"year":2012,"finding":"Endogenous FAT10 conjugates include the autophagy adaptor p62/SQSTM1 as a covalent mono-FAT10ylated substrate at multiple lysines; FAT10 colocalizes with p62 in p62 bodies; FAT10ylation of p62 leads to its proteasomal degradation; mass spectrometry identified 569 FAT10-interacting proteins including HDAC6 and UBA6.","method":"Immunopurification of endogenous FAT10 conjugates, mass spectrometry, co-immunoprecipitation, colocalization imaging, proteasome inhibitor treatment","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mass spectrometry-based substrate identification with functional validation of p62 FAT10ylation and degradation, multiple orthogonal methods","pmids":["22797925"],"is_preprint":false},{"year":2012,"finding":"FAT10 modification promotes MHC class I antigen presentation of viral pp65 antigen; this presentation partially relies on Rpn10 and is supported by NUB1 but is not influenced by immunoproteasomes or PA28, distinguishing FAT10 from ubiquitin-dependent presentation.","method":"Antigen presentation assays, proteasome inhibitor treatment, siRNA knockdown of pathway components","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional antigen presentation assays with mechanistic knockdowns, single lab","pmids":["22349260"],"is_preprint":false},{"year":2012,"finding":"AIPL1 (LCA blindness protein) binds noncovalently to free FAT10 and FAT10ylated proteins, forms a ternary complex with FAT10 and NUB1, and antagonizes NUB1-mediated FAT10-DHFR degradation; AIPL1 also co-immunoprecipitates UBA6.","method":"Co-immunoprecipitation, degradation assay, AIPL1 mutant analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with functional degradation assay and mutant analysis, single lab","pmids":["22347407"],"is_preprint":false},{"year":2012,"finding":"FAT10 covalently modifies LRRFIP2 at two distinct sites; FATylation of LRRFIP2 translocates it to the cellular insoluble fraction, preventing its membrane recruitment with MYD88 and thereby inhibiting TLR4-mediated NF-κB activation.","method":"Co-immunoprecipitation, subcellular fractionation, NF-κB reporter assay, LPS stimulation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — covalent modification confirmed with functional pathway readout, single lab","pmids":["23036196"],"is_preprint":false},{"year":2012,"finding":"Uba6 activates FAT10 through a three-step mechanism similar to Uba1 (adenylation and thioester formation); FAT10 binds Uba6 with higher affinity than ubiquitin but shows lower catalytic activity in E1-E2 transthiolation; FAT10 forms a ternary complex with Uba6 together with ubiquitin.","method":"Biochemical kinetics, ATP-PPi exchange assay, E1-E2 transthiolation assay, mechanism-based E1 inhibitor studies, biophysical binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous in vitro enzymatic characterization with pre-steady state kinetics and inhibitor studies","pmids":["22427669"],"is_preprint":false},{"year":2014,"finding":"The MAD2-binding interface of FAT10 is located on its first ubiquitin-like domain; NMR structure of this domain was determined; mutation of specific MAD2-binding residues abrogates FAT10-MAD2 interaction without disrupting FAT10's other interactions; disruption of FAT10-MAD2 binding dramatically reduces FAT10-mediated tumor growth, aneuploidy, proliferation, migration, invasion, and apoptosis resistance.","method":"NMR structure determination, site-directed mutagenesis, co-immunoprecipitation, in vitro and in vivo tumor assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure plus mutagenesis plus functional validation in vitro and in vivo, multiple orthogonal methods","pmids":["25422469"],"is_preprint":false},{"year":2014,"finding":"FAT10 directly binds β-catenin, preventing its ubiquitination and degradation, thereby activating the β-catenin/TCF4 pathway and upregulating HOXB9 expression to promote HCC invasion and metastasis.","method":"Co-immunoprecipitation, RNAi knockdown, rescue experiments with HOXB9 overexpression, in vitro invasion assays, in vivo mouse models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with functional rescue experiments, single lab, in vitro and in vivo validation","pmids":["25056121"],"is_preprint":false},{"year":2014,"finding":"FAT10 decorates cytosolic Salmonella Typhimurium in human cells; FAT10-decorated bacteria colocalize with ubiquitin, p62, NDP52, and LC3B; FAT10 colocalizes with p62-positive microdomains; FAT10-deficient NRAMP1-transgenic mice show higher susceptibility to oral S. Typhimurium infection.","method":"Immunofluorescence colocalization, siRNA knockdown, FAT10-deficient mouse infection model","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct imaging with genetic mouse model validation, single lab","pmids":["25271057"],"is_preprint":false},{"year":2015,"finding":"UBE1 (ubiquitin E1) is a substrate of FAT10; FAT10ylation of UBE1 depends on the diglycine motif of FAT10 and the UBA6/USE1 conjugation pathway; FAT10ylated UBE1 undergoes proteasomal degradation; UBE1 does not act as a second E1 for FAT10.","method":"Co-immunoprecipitation, mass spectrometry, siRNA knockdown of UBA6/USE1, proteasome inhibitor treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous conjugate confirmed with pathway-specific knockdowns and proteasome inhibition, single lab","pmids":["25768649"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of USE1 (UBE2Z) reveals domain organization; specificity of FAT10 conjugation toward UBA6 and USE1 lies within the C-terminal CYCI tetrapeptide of FAT10; this motif slows the transfer rate of FAT10 from UBA6 onto USE1.","method":"X-ray crystallography, site-directed mutagenesis, biochemical transfer assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis plus biochemical assays in single study","pmids":["26555268"],"is_preprint":false},{"year":2015,"finding":"FAT10 is selectively expressed in medullary thymic epithelial cells (mTECs) and alters the repertoire of MHC class I-presented peptides and thymic negative selection; FAT10-deficient mice show altered T cell repertoire and impaired negative selection in TCR-transgenic models.","method":"FAT10-/- mice, TCR Vβ-segment screening, MHC class I peptide elution, TCR-transgenic mouse analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with MHC peptide repertoire analysis and functional T cell selection readouts, single lab","pmids":["26401002"],"is_preprint":false},{"year":2016,"finding":"FAT10 competes with ubiquitin for binding to the same lysines on eEF1A1; FAT10 overexpression decreases ubiquitin-eEF1A1 conjugates and increases FAT10-eEF1A1 conjugates, stabilizing eEF1A1 and promoting cancer cell proliferation.","method":"Co-immunoprecipitation, ubiquitination assays, lysine mutants, Western blot, proliferation assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — competition assay with lysine mutants and dual conjugate detection, single lab","pmids":["27312528"],"is_preprint":false},{"year":2016,"finding":"FAT10 noncovalently associates with the 2CARD domain of RIG-I; FAT10 inhibits viral RNA-induced IRF3 and NF-κB activation by modulating RIG-I protein solubility; FAT10 is recruited to the RIG-I-TRIM25 complex where it is stabilized by TRIM25; FAT10 sequesters active RIG-I away from mitochondria and inhibits antiviral stress granule formation.","method":"Co-immunoprecipitation, domain mapping, luciferase reporter assay, fractionation/solubility assay, immunofluorescence colocalization","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain specificity, multiple functional readouts, single lab","pmids":["26996158"],"is_preprint":false},{"year":2018,"finding":"FAT10 directly binds to Nav1.5 at lysine residues in its C-terminal fragments and prevents Nedd4-2 (ubiquitin E3 ligase) binding, stabilizing Nav1.5 membrane expression; cardiac-specific Fat10 knockout causes reduced peak Na+ current, increased late Na+ current, and ventricular arrhythmia after myocardial infarction.","method":"Cardiac-specific Cre-lox knockout, patch-clamp electrophysiology, co-immunoprecipitation, immunofluorescence","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic cardiac-specific KO with electrophysiology, Co-IP mapping interaction site, multiple orthogonal readouts","pmids":["33414395"],"is_preprint":false},{"year":2018,"finding":"High-resolution NMR/crystal structures of the two individual ubiquitin-like domains (UBDs) of FAT10 show typical ubiquitin-fold but entirely different surface properties from each other and from ubiquitin; deletion of the flexible linker abrogates FAT10 conjugation; mutation of the linker blocks USE1 auto-FAT10ylation but not bulk conjugate formation; FAT10-mediated degradation is independent of VCP/p97 when FAT10's unstructured N-terminal heptapeptide is present; intrinsic instability of FAT10 enables rapid co-degradation of FAT10 and its substrates without de-conjugation.","method":"NMR structure, domain deletion and mutagenesis, in vitro degradation assays, VCP/p97 inhibition","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution structure with mutagenesis and functional in vitro assays, multiple orthogonal methods","pmids":["30127417"],"is_preprint":false},{"year":2018,"finding":"UBD/FAT10 expression inversely correlates with APOL1 G1/G2 variant-mediated cell toxicity; disease-associated APOL1 alleles increase UBD mRNA but decrease UBD protein; UBD appears to mitigate APOL1-mediated toxicity by targeting APOL1 for proteasomal degradation.","method":"Admixture mapping, cell-based expression assays, Western blot, cell toxicity assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cell-based assays with correlation data, no direct biochemical demonstration of FAT10-APOL1 conjugation, single study","pmids":["29531077"],"is_preprint":false},{"year":2019,"finding":"FAT10 directly binds to and impedes the SUMO E1 activating enzyme AOS1/UBA2, competing with SUMO for activation and thioester formation in vitro; FAT10 overexpression downregulates SUMO conjugation and SUMO-dependent PML body formation in cells; activation of FAT10 by AOS1/UBA2 does not lead to covalent FAT10 conjugation to substrates.","method":"In vitro thioester formation assay, competition assay, Western blot, immunofluorescence of PML bodies","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution showing direct competition with mechanistic dissection, cellular validation with functional readout","pmids":["31575873"],"is_preprint":false},{"year":2019,"finding":"ZNF598 delivers FAT10 to RIG-I, resulting in inhibition of RIG-I polyubiquitination required for downstream IFN signaling; ZNF598 ubiquitin ligase activity is dispensable for this suppression; ZNF598-mediated suppression is abolished by FAT10 knockout.","method":"Co-immunoprecipitation, FAT10 knockout cells, RIG-I ubiquitination assay, IFN reporter assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout validation with mechanism of polyubiquitination inhibition, single lab","pmids":["31433974"],"is_preprint":false},{"year":2019,"finding":"FAT10 noncovalently interacts with OTUB1 and stimulates its deubiquitylase activity toward Lys-48-linked diubiquitin; covalent FAT10ylation of OTUB1 leads to its proteasomal degradation; FAT10-OTUB1 interaction also strengthens OTUB1's noncatalytic inhibition of Lys-63 polyubiquitylation of TRAF3; FAT10 increases OTUB1 interaction with UbcH5B.","method":"Co-immunoprecipitation, in vitro DUB activity assay, co-immunoprecipitation with E2 enzyme, proteasome inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro enzymatic assays with cellular validation, single lab, multiple functional readouts","pmids":["30718280"],"is_preprint":false},{"year":2020,"finding":"FAT10 directly interacts with PPARα in hepatocytes; FAT10 silencing increases PPARα target gene expression and promotes fatty acid oxidation; FAT10 overexpression in vivo inhibits PPARα lipid regulatory activity in response to fasting and agonist treatment.","method":"Co-immunoprecipitation, siRNA knockdown, in vivo hepatocyte FAT10 overexpression, fatty acid oxidation assay","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with in vivo functional validation, single lab","pmids":["37926201"],"is_preprint":false},{"year":2021,"finding":"Parkin is an E3 ligase for FAT10; FAT10 becomes conjugated to Parkin and targets it for proteasomal degradation; Parkin binds the FAT10 E2 enzyme USE1 and auto-FAT10ylates itself; Parkin facilitates FAT10ylation of Mitofusin2 in vitro and in cells; on mitochondrial depolarization, FAT10ylation of Parkin inhibits its ubiquitin-ligase activity and impairs mitophagy.","method":"In vitro FAT10ylation assay, co-immunoprecipitation, proteasome inhibitor treatment, mitochondrial depolarization assay, dopaminergic cell death assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro reconstitution of E3 ligase activity plus cellular validation of mitophagy impairment, multiple orthogonal methods","pmids":["33730565"],"is_preprint":false},{"year":2021,"finding":"UBD/FAT10 interacts with p53 in colorectal cancer cells, promotes its proteasomal degradation, and shortens p53 half-life, leading to decreased p21 and increased cyclins/CDKs and cell proliferation; in vivo tumor growth driven by UBD depends on p53 decrease.","method":"Co-immunoprecipitation, cycloheximide chase, proteasome inhibitor treatment, xenograft mouse model","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, half-life assay, in vivo rescue experiment, single lab","pmids":["34350116"],"is_preprint":false},{"year":2022,"finding":"Crystal structures of human Uba6 in complex with ubiquitin reveal two conformations: open (adenylation-active) and closed (thioester-active); an allosteric inositol hexakisphosphate (InsP6) binding site on Uba6 inhibits its activity by altering open-closed conformational interconversion; these structures provide the molecular basis for FAT10 and ubiquitin activation.","method":"X-ray crystallography, biochemical activity assays, biophysical binding assays, site-directed mutagenesis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures with biochemical and biophysical validation of allosteric mechanism","pmids":["35986001"],"is_preprint":false},{"year":2022,"finding":"FAT10 directly binds FOXM1 and stabilizes it by competing with ubiquitin for binding to FOXM1, inhibiting ubiquitination-mediated FOXM1 degradation, thereby promoting EMT and gemcitabine resistance in pancreatic cancer.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, rescue experiments","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with competition-based ubiquitination assay and functional rescue, single lab","pmids":["35614040"],"is_preprint":false},{"year":2023,"finding":"FAT10 directly binds Smad3 at K378 via its C-terminal glycine residues and mediates Smad3 degradation through the FAT10-proteasome system independently of ubiquitin; FAT10-/- mice show excessive cardiac fibrosis after myocardial infarction; FAT10 restoration suppresses fibrosis in a Smad3-dependent manner.","method":"IP-mass spectrometry, co-immunoprecipitation, FAT10-/- mouse model, in vivo rescue, in vitro fibroblast assays","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IP-MS substrate identification with genetic mouse model validation and site-specific binding data, single lab","pmids":["36778114"],"is_preprint":false},{"year":2023,"finding":"FAT10 and NUB1L cooperate to activate 26S proteasome gate opening in a ubiquitin- and USP14-independent manner; FAT10 binding to UBA domains of NUB1L interferes with NUB1L dimerization, increasing NUB1L affinity for RPN1 and thereby activating proteasomal peptidolytic activities.","method":"In vitro proteasome activity assay, co-immunoprecipitation, domain binding assays","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assays with mechanistic dissection, single lab","pmids":["37188463"],"is_preprint":false},{"year":2024,"finding":"FAT10 structural plasticity (lower thermodynamic stability, faster mechanical unfolding, absent long-range salt bridges, partially unstructured regions) is critical for its function as a proteasomal degradation tag; Fat10's unfolding destabilizes conjugated substrates creating partially unstructured regions that enhance proteasomal engagement and degradation rate.","method":"NMR relaxation analysis, hydrogen-deuterium exchange, temperature-dependent chemical shift, force spectroscopy (mechanical unfolding), in vitro degradation assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple structural and biophysical methods with in vitro degradation validation, rigorous mechanistic dissection","pmids":["38984715"],"is_preprint":false},{"year":2025,"finding":"NUB1 uses intrinsic instability of FAT10 to trap its N-terminal ubiquitin-like domain in an unfolded state and deliver it to the 26S proteasome for engagement; cryo-EM structures visualize the NUB1 complex bound to proteasomal Rpn1 during FAT10 delivery; this delivery is ubiquitin-independent and p97-independent; NUB1 binding activates NUB1 for proteasomal docking.","method":"In vitro reconstitution, hydrogen-deuterium exchange, cryo-EM, structural modeling, site-directed mutagenesis","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure plus in vitro reconstitution plus HDX and mutagenesis, multiple orthogonal methods in single rigorous study","pmids":["40217121"],"is_preprint":false},{"year":2020,"finding":"FAT10 inhibits PDE6 cGMP hydrolyzing activity by noncovalently interacting with PDE6 GAFa and catalytic domains; FAT10 also covalently conjugates to rod PDE6 and targets it for proteasomal degradation; AIPL1 stabilizes both FAT10 monomer and the PDE6-FAT10 conjugate.","method":"In vitro PDE6 activity assay, co-immunoprecipitation, proteasome inhibitor treatment, domain interaction mapping","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro enzymatic assay with cellular validation, single lab, multiple readouts","pmids":["32817338"],"is_preprint":false},{"year":2022,"finding":"FAT10 directly binds to EGFR and inhibits its ubiquitination and degradation, stabilizing EGFR expression; this stabilization upregulates PFKFB3 via the EGFR/AKT pathway, promoting glycolysis and osteosarcoma growth.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, in vitro and in vivo proliferation assays","journal":"American journal of cancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and ubiquitination assay, indirect pathway linkage, single lab","pmids":["32775001"],"is_preprint":false},{"year":2019,"finding":"FAT10 directly interacts with and stabilizes the deubiquitylating enzyme USP7; FAT10-USP7 interaction mediates CHK1 upregulation, prolonging CHK1-mediated G2/M arrest in renal tubular epithelial cells exposed to hypoxia, promoting pro-fibrotic cytokine production.","method":"Co-immunoprecipitation, FAT10-/- mouse-derived cells, Western blot, cell cycle analysis","journal":"Aging","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP with genetic cell model, indirect pathway linkage, single lab","pmids":["36152057"],"is_preprint":false},{"year":2020,"finding":"FAT10 suppresses autophagy by competing with SUMO1 at the K734 modification site of SIRT1, reducing SIRT1 nuclear translocation and activity via its C-terminal glycine residues; this reduces LC3 deacetylation and suppresses autophagosome formation, protecting the heart from ischemic injury.","method":"Co-immunoprecipitation, FAT10-knockout rat model, SIRT1 SUMOylation assay, autophagy flux assay, in vivo/in vitro ischemia models","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with mechanistic competition assay and functional autophagy readout, single lab","pmids":["33307094"],"is_preprint":false},{"year":2014,"finding":"FAT10 promotes NF-κB activation, which upregulates CXCR4 and CXCR7 chemokine receptors; siRNA depletion of CXCR7 and CXCR4 attenuates invasion of FAT10-overexpressing cells, establishing the NF-κB-CXCR4/7 pathway as the mechanism for FAT10-induced malignant transformation.","method":"NF-κB reporter assay, siRNA knockdown, invasion assays, anchorage-independent growth, in vivo tumor formation","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection with siRNA rescue, in vitro and in vivo validation, single lab","pmids":["24325913"],"is_preprint":false}],"current_model":"FAT10 (UBD) is a cytokine-inducible (IFNγ+TNFα) ubiquitin-like modifier encoded in the MHC class I locus that is activated by the E1 enzyme UBA6 via adenylation and thioester formation, transferred to the dedicated E2 enzyme USE1 (which auto-FAT10ylates itself in cis), and covalently conjugated to hundreds of substrate proteins via an isopeptide bond to internal lysines, targeting them for ubiquitin-independent but NUB1L-dependent 26S proteasomal degradation through docking of FAT10/NUB1L to the VWA domain of Rpn10 and Rpn1; FAT10's intrinsic structural plasticity and low thermodynamic stability are critical for enabling the proteasomal engagement that co-degrades FAT10 and substrate without de-conjugation, while NUB1L traps FAT10's unfolded N-terminal domain to deliver it to the proteasome; noncovalently, FAT10 interacts with MAD2 (disrupting kinetochore localization and causing chromosomal instability), RIG-I (sequestering it from its signaling platform to suppress antiviral signaling), OTUB1 (stimulating its deubiquitylase activity), β-catenin and multiple protein substrates (competing with ubiquitin to stabilize them), HDAC6 (enabling aggresome transport when proteasome is impaired), and the SUMO E1 enzyme AOS1/UBA2 (inhibiting SUMO activation and conjugation); Parkin has been identified as an E3 ligase for FAT10 that mediates auto-FAT10ylation and Mitofusin2 FAT10ylation, while FAT10ylation of Parkin in turn inhibits mitophagy; FAT10 expression is transcriptionally regulated by NF-κB, STAT3, and IFNγ-responsive elements, and is negatively regulated by p53."},"narrative":{"mechanistic_narrative":"FAT10 (UBD) is a ubiquitin-like protein modifier that conjugates to target proteins through its C-terminal diglycine motif and directs them, together with itself, to the 26S proteasome for degradation [PMID:11445583, PMID:15831455]. Activation proceeds through a dedicated enzymatic cascade: the E1 enzyme UBA6 activates FAT10 by adenylation and thioester formation requiring its active-site cysteine and FAT10's diglycine motif [PMID:17889673, PMID:22427669], and transfers it to the E2 enzyme USE1, which auto-FAT10ylates itself in cis and is the first identified substrate of the pathway [PMID:20975683]; specificity for UBA6/USE1 is encoded in FAT10's C-terminal CYCI tetrapeptide [PMID:26555268], and Parkin acts as an E3 ligase that drives auto-FAT10ylation and modification of Mitofusin2 [PMID:33730565]. FAT10-mediated proteolysis is ubiquitin-independent and instead requires NUB1L, which docks FAT10 to the proteasome via the VWA domain of Rpn10 and via Rpn1 [PMID:14757770, PMID:19166848, PMID:22434192]; NUB1 exploits FAT10's intrinsic structural plasticity and low thermodynamic stability to trap its unfolded N-terminal domain and deliver it to the proteasome, enabling co-degradation of FAT10 and substrate without de-conjugation [PMID:30127417, PMID:38984715, PMID:40217121]. Beyond covalent conjugation, FAT10 acts noncovalently to stabilize or sequester binding partners: it binds the SUMO E1 AOS1/UBA2 to inhibit SUMO activation [PMID:31575873], the spindle-checkpoint protein MAD2 to displace it from kinetochores and drive chromosomal instability [PMID:16495226, PMID:25422469], and competes with ubiquitin on shared lysines of substrates such as β-catenin to stabilize them and promote oncogenic signaling [PMID:25056121, PMID:27312528]. FAT10 is induced by TNF-α/NF-κB signaling and negatively regulated by p53 [PMID:16501612, PMID:22025632], and functions in immune regulation, antiviral signaling through RIG-I suppression [PMID:26996158, PMID:31433974], antigen presentation and thymic selection [PMID:22349260, PMID:26401002], and mitochondrial quality control by inhibiting Parkin-dependent mitophagy [PMID:33730565].","teleology":[{"year":1999,"claim":"Established the first FAT10 binding partner, linking the protein to mitotic checkpoint control before its enzymology was understood.","evidence":"Yeast two-hybrid screen and reciprocal co-IP identifying MAD2 association","pmids":["10200259"],"confidence":"Medium","gaps":["Interaction interface not mapped at this stage","Functional consequence for the checkpoint not yet demonstrated"]},{"year":2001,"claim":"Demonstrated that FAT10 is a covalent protein modifier whose conjugation depends on its C-terminal diglycine and has cellular consequences.","evidence":"Tetracycline-repressible expression with diglycine mutant and apoptosis readouts in mouse fibroblasts","pmids":["11445583"],"confidence":"Medium","gaps":["Conjugating enzymes unidentified","Substrate identities unknown"]},{"year":2005,"claim":"Defined FAT10 as a proteasomal degradation signal acting independently of ubiquitin, distinguishing it from canonical ubiquitin-mediated turnover.","evidence":"Cycloheximide chase, proteasome inhibition, lysine-mutant FAT10, ubiquitylation-deficient cells and FAT10-GFP fusion assays","pmids":["15831455"],"confidence":"High","gaps":["Mechanism of proteasome docking not yet resolved","A 2011 study (#13) reported ubiquitin-dependence, leaving the requirement contested"]},{"year":2007,"claim":"Identified UBA6 as the activating E1 enzyme, establishing the entry point of the FAT10 conjugation cascade.","evidence":"In vitro thioester assay with active-site cysteine mutagenesis plus cellular RNAi","pmids":["17889673"],"confidence":"High","gaps":["Downstream E2 not yet identified at this point"]},{"year":2010,"claim":"Identified USE1 as the dedicated E2 and first pathway substrate, completing the E1-E2 transfer chain and revealing cis auto-modification.","evidence":"In vitro FAT10 transfer assay, cis vs trans auto-FAT10ylation, siRNA knockdown","pmids":["20975683"],"confidence":"High","gaps":["E3 ligases for general substrates not defined","Mechanism of cis-only auto-modification unexplained"]},{"year":2009,"claim":"Established NUB1L as the strict cofactor coupling FAT10 to the proteasome, explaining ubiquitin-independent delivery.","evidence":"In vitro degradation of FAT10-DHFR by purified 26S proteasome and cellular NUB1L knockdown","pmids":["19166848","14757770"],"confidence":"High","gaps":["Structural basis of NUB1L-FAT10-proteasome engagement not yet resolved"]},{"year":2012,"claim":"Mapped the proteasomal docking site, showing FAT10/NUB1L engage the Rpn10 VWA domain and Rpn1, providing the receptor for ubiquitin-independent delivery.","evidence":"Co-IP, domain mapping, siRNA depletion and yeast complementation with VWA-only Rpn10","pmids":["22434192"],"confidence":"High","gaps":["How the engaged substrate is unfolded at the proteasome not addressed","Stoichiometry of the delivery complex unknown"]},{"year":2012,"claim":"Defined the endogenous FAT10 substrate landscape by proteomics, anchoring FAT10 to autophagy and confirming hundreds of conjugates.","evidence":"Immunopurification of endogenous conjugates with mass spectrometry identifying 569 interactors and validating p62/SQSTM1 modification","pmids":["22797925"],"confidence":"High","gaps":["Site-specific modification stoichiometry on most substrates unknown","Functional consequence beyond p62 degradation not established"]},{"year":2014,"claim":"Localized the MAD2-binding interface to FAT10's first UBL domain and showed its disruption abolishes pro-tumorigenic activity, separating a noncovalent function from conjugation.","evidence":"NMR structure, residue-specific mutagenesis, and in vitro/in vivo tumor assays","pmids":["25422469"],"confidence":"High","gaps":["How displaced MAD2 fails to localize to kinetochores mechanistically unresolved"]},{"year":2016,"claim":"Demonstrated that FAT10 stabilizes oncogenic substrates by directly competing with ubiquitin for shared lysines.","evidence":"Co-IP, lysine-mutant analysis and dual conjugate detection on eEF1A1, alongside β-catenin stabilization (#21)","pmids":["27312528","25056121"],"confidence":"Medium","gaps":["Generality of competition versus active conjugation across substrates not quantified"]},{"year":2019,"claim":"Revealed a noncovalent regulatory function: FAT10 inhibits SUMO activation by directly impeding the SUMO E1, expanding its role beyond degradation.","evidence":"In vitro thioester competition assay and cellular PML-body and SUMO-conjugation readouts","pmids":["31575873"],"confidence":"High","gaps":["In vivo consequences of SUMO suppression not defined"]},{"year":2021,"claim":"Identified Parkin as a FAT10 E3 ligase and a reciprocal regulatory loop in which FAT10ylation of Parkin inhibits mitophagy.","evidence":"In vitro FAT10ylation reconstitution, co-IP, and mitochondrial depolarization assays","pmids":["33730565"],"confidence":"High","gaps":["Whether other E3 ligases serve different substrate classes unknown"]},{"year":2024,"claim":"Explained why FAT10 functions as a degron: its intrinsic structural instability and rapid unfolding promote proteasomal engagement and destabilize attached substrates.","evidence":"NMR relaxation, hydrogen-deuterium exchange, force spectroscopy and in vitro degradation assays","pmids":["38984715","30127417"],"confidence":"High","gaps":["Behavior on physiological multi-domain substrates in vivo not fully tested"]},{"year":2025,"claim":"Visualized the delivery mechanism, showing NUB1 traps FAT10's unfolded N-terminal UBL and docks it to proteasomal Rpn1 independently of ubiquitin and p97.","evidence":"Cryo-EM, in vitro reconstitution, HDX and mutagenesis of the NUB1-proteasome complex","pmids":["40217121"],"confidence":"High","gaps":["Hand-off from NUB1 to the ATPase translocation channel not resolved","Regulation of NUB1 activation in cells unclear"]},{"year":null,"claim":"How FAT10 substrate selection is achieved for its hundreds of conjugates, and what E3 ligases beyond Parkin direct specific FAT10ylation, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No general substrate-recognition code defined","Few E3 ligases identified","Balance between covalent conjugation and noncovalent sequestration per substrate unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0031386","term_label":"protein tag activity","supporting_discovery_ids":[1,3,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,20,27,31,33]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[27,31]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,7,15]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[9,46]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,8,14,42]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[16,25,27,32]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,20]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[35,46]}],"complexes":[],"partners":["UBA6","USE1","NUB1L","MAD2","RPN10","HDAC6","OTUB1","AOS1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15205","full_name":"Ubiquitin D","aliases":["Diubiquitin","Ubiquitin-like protein FAT10"],"length_aa":165,"mass_kda":18.5,"function":"Ubiquitin-like protein modifier which can be covalently attached to target proteins and subsequently leads to their degradation by the 26S proteasome, in a NUB1-dependent manner (PubMed:15831455, PubMed:16707496, PubMed:19166848). Conjugation to the target protein is activated by UBA6 via adenylation of its C-terminal glycine (PubMed:17889673, PubMed:35970836). Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha (PubMed:19959714). Required for TNF-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses (PubMed:19028597). Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle (PubMed:16495226). May be involved in the formation of aggresomes when proteasome is saturated or impaired (PubMed:19033385). Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) (PubMed:16495380)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O15205/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/UBD","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/UBD","total_profiled":1310},"omim":[{"mim_id":"620543","title":"ZINC FINGER CONTAINING UBIQUITIN PEPTIDASE 1; ZUP1","url":"https://www.omim.org/entry/620543"},{"mim_id":"611361","title":"UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME 6; UBA6","url":"https://www.omim.org/entry/611361"},{"mim_id":"606050","title":"UBIQUITIN D; UBD","url":"https://www.omim.org/entry/606050"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli fibrillar center","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":141.8}],"url":"https://www.proteinatlas.org/search/UBD"},"hgnc":{"alias_symbol":["FAT10"],"prev_symbol":[]},"alphafold":{"accession":"O15205","domains":[{"cath_id":"3.10.20.90","chopping":"9-79","consensus_level":"high","plddt":86.8423,"start":9,"end":79},{"cath_id":"3.10.20.90","chopping":"88-161","consensus_level":"high","plddt":89.8705,"start":88,"end":161}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15205","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15205-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15205-F1-predicted_aligned_error_v6.png","plddt_mean":85.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UBD","jax_strain_url":"https://www.jax.org/strain/search?query=UBD"},"sequence":{"accession":"O15205","fasta_url":"https://rest.uniprot.org/uniprotkb/O15205.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15205/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15205"}},"corpus_meta":[{"pmid":"15831455","id":"PMC_15831455","title":"FAT10, a ubiquitin-independent signal for proteasomal degradation.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15831455","citation_count":181,"is_preprint":false},{"pmid":"17889673","id":"PMC_17889673","title":"E1-L2 activates both ubiquitin and FAT10.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17889673","citation_count":162,"is_preprint":false},{"pmid":"12730673","id":"PMC_12730673","title":"Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12730673","citation_count":153,"is_preprint":false},{"pmid":"11445583","id":"PMC_11445583","title":"The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11445583","citation_count":149,"is_preprint":false},{"pmid":"10200259","id":"PMC_10200259","title":"A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10200259","citation_count":143,"is_preprint":false},{"pmid":"18574467","id":"PMC_18574467","title":"Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18574467","citation_count":140,"is_preprint":false},{"pmid":"25056121","id":"PMC_25056121","title":"Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying β-catenin degradation.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25056121","citation_count":111,"is_preprint":false},{"pmid":"16782901","id":"PMC_16782901","title":"FAT10/diubiquitin-like protein-deficient mice exhibit minimal phenotypic differences.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16782901","citation_count":92,"is_preprint":false},{"pmid":"14757770","id":"PMC_14757770","title":"NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14757770","citation_count":86,"is_preprint":false},{"pmid":"20975683","id":"PMC_20975683","title":"USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis.","date":"2010","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/20975683","citation_count":85,"is_preprint":false},{"pmid":"22797925","id":"PMC_22797925","title":"The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22797925","citation_count":81,"is_preprint":false},{"pmid":"19959714","id":"PMC_19959714","title":"The ubiquitin-like protein FAT10 mediates NF-kappaB activation.","date":"2009","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19959714","citation_count":79,"is_preprint":false},{"pmid":"16495380","id":"PMC_16495380","title":"Role of ubiquitin-like protein FAT10 in epithelial apoptosis in renal disease.","date":"2006","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/16495380","citation_count":76,"is_preprint":false},{"pmid":"27393295","id":"PMC_27393295","title":"The ubiquitin-like modifier FAT10 in cancer development.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27393295","citation_count":74,"is_preprint":false},{"pmid":"22434192","id":"PMC_22434192","title":"FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis.","date":"2012","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/22434192","citation_count":73,"is_preprint":false},{"pmid":"16495226","id":"PMC_16495226","title":"FAT10 plays a role in the regulation of chromosomal stability.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16495226","citation_count":72,"is_preprint":false},{"pmid":"19166848","id":"PMC_19166848","title":"Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L.","date":"2009","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19166848","citation_count":68,"is_preprint":false},{"pmid":"19033385","id":"PMC_19033385","title":"The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/19033385","citation_count":67,"is_preprint":false},{"pmid":"27312528","id":"PMC_27312528","title":"The Ubiquitin-like Protein FAT10 Stabilizes eEF1A1 Expression to Promote Tumor Proliferation in a Complex Manner.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27312528","citation_count":65,"is_preprint":false},{"pmid":"16501612","id":"PMC_16501612","title":"p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16501612","citation_count":64,"is_preprint":false},{"pmid":"22025632","id":"PMC_22025632","title":"FAT10 mediates the effect of TNF-α in inducing chromosomal instability.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22025632","citation_count":61,"is_preprint":false},{"pmid":"29531077","id":"PMC_29531077","title":"UBD modifies APOL1-induced kidney disease risk.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29531077","citation_count":58,"is_preprint":false},{"pmid":"24518302","id":"PMC_24518302","title":"NFκB and STAT3 synergistically activate the expression of FAT10, a gene counteracting the tumor suppressor p53.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24518302","citation_count":57,"is_preprint":false},{"pmid":"25422469","id":"PMC_25422469","title":"Disruption of FAT10-MAD2 binding inhibits tumor progression.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25422469","citation_count":56,"is_preprint":false},{"pmid":"25271057","id":"PMC_25271057","title":"The ubiquitin-like modifier FAT10 decorates autophagy-targeted Salmonella and contributes to Salmonella resistance in mice.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25271057","citation_count":56,"is_preprint":false},{"pmid":"18280469","id":"PMC_18280469","title":"Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis.","date":"2008","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18280469","citation_count":56,"is_preprint":false},{"pmid":"16959044","id":"PMC_16959044","title":"FAT10, a gene up-regulated in various cancers, is cell-cycle regulated.","date":"2006","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/16959044","citation_count":52,"is_preprint":false},{"pmid":"16702978","id":"PMC_16702978","title":"UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells.","date":"2006","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16702978","citation_count":50,"is_preprint":false},{"pmid":"26996158","id":"PMC_26996158","title":"Ubiquitin-like modifier FAT10 attenuates RIG-I mediated antiviral signaling by segregating activated RIG-I from its signaling platform.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26996158","citation_count":49,"is_preprint":false},{"pmid":"24706839","id":"PMC_24706839","title":"Extended lifespan and reduced adiposity in mice lacking the FAT10 gene.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24706839","citation_count":48,"is_preprint":false},{"pmid":"24325913","id":"PMC_24325913","title":"FAT10, an ubiquitin-like protein, confers malignant properties in non-tumorigenic and tumorigenic cells.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24325913","citation_count":46,"is_preprint":false},{"pmid":"19726511","id":"PMC_19726511","title":"FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy.","date":"2009","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19726511","citation_count":45,"is_preprint":false},{"pmid":"33730565","id":"PMC_33730565","title":"Parkin is an E3 ligase for the ubiquitin-like modifier FAT10, which inhibits Parkin activation and mitophagy.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33730565","citation_count":45,"is_preprint":false},{"pmid":"22072791","id":"PMC_22072791","title":"FAT10 is a proteasomal degradation signal that is itself regulated by ubiquitination.","date":"2011","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22072791","citation_count":43,"is_preprint":false},{"pmid":"30127417","id":"PMC_30127417","title":"The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30127417","citation_count":42,"is_preprint":false},{"pmid":"19437562","id":"PMC_19437562","title":"FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging.","date":"2009","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19437562","citation_count":41,"is_preprint":false},{"pmid":"32719056","id":"PMC_32719056","title":"The ubiquitin-like modifier FAT10 - much more than a proteasome-targeting signal.","date":"2020","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/32719056","citation_count":39,"is_preprint":false},{"pmid":"20433827","id":"PMC_20433827","title":"The role of cytokines in UbD promoter regulation and Mallory-Denk body-like aggresomes.","date":"2010","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20433827","citation_count":39,"is_preprint":false},{"pmid":"22349260","id":"PMC_22349260","title":"The FAT10- and ubiquitin-dependent degradation machineries exhibit common and distinct requirements for MHC class I antigen presentation.","date":"2012","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/22349260","citation_count":38,"is_preprint":false},{"pmid":"29458176","id":"PMC_29458176","title":"GRP78 Promotes Hepatocellular Carcinoma proliferation by increasing FAT10 expression through the NF-κB pathway.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29458176","citation_count":35,"is_preprint":false},{"pmid":"27806337","id":"PMC_27806337","title":"Ubiquitin-like protein FAT10 promotes bladder cancer progression by stabilizing survivin.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27806337","citation_count":35,"is_preprint":false},{"pmid":"29438664","id":"PMC_29438664","title":"FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3.","date":"2018","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29438664","citation_count":33,"is_preprint":false},{"pmid":"31575873","id":"PMC_31575873","title":"The ubiquitin-like modifier FAT10 interferes with SUMO activation.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31575873","citation_count":31,"is_preprint":false},{"pmid":"23416168","id":"PMC_23416168","title":"FAT10 protects cardiac myocytes against apoptosis.","date":"2013","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23416168","citation_count":31,"is_preprint":false},{"pmid":"22427669","id":"PMC_22427669","title":"Mechanistic studies on activation of ubiquitin and di-ubiquitin-like protein, FAT10, by ubiquitin-like modifier activating enzyme 6, Uba6.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22427669","citation_count":31,"is_preprint":false},{"pmid":"31433974","id":"PMC_31433974","title":"Attenuation of the Innate Immune Response against Viral Infection Due to ZNF598-Promoted Binding of FAT10 to RIG-I.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31433974","citation_count":31,"is_preprint":false},{"pmid":"26555268","id":"PMC_26555268","title":"Structure of UBE2Z Enzyme Provides Functional Insight into Specificity in the FAT10 Protein Conjugation Machinery.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26555268","citation_count":30,"is_preprint":false},{"pmid":"31067743","id":"PMC_31067743","title":"UBA6 and Its Bispecific Pathways for Ubiquitin and FAT10.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31067743","citation_count":29,"is_preprint":false},{"pmid":"25983082","id":"PMC_25983082","title":"The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense.","date":"2015","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25983082","citation_count":29,"is_preprint":false},{"pmid":"35614040","id":"PMC_35614040","title":"FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35614040","citation_count":27,"is_preprint":false},{"pmid":"30718280","id":"PMC_30718280","title":"The ubiquitin-like modifier FAT10 stimulates the activity of deubiquitylating enzyme OTUB1.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30718280","citation_count":27,"is_preprint":false},{"pmid":"31877302","id":"PMC_31877302","title":"Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31877302","citation_count":26,"is_preprint":false},{"pmid":"32775001","id":"PMC_32775001","title":"Ubiquitin-like protein FAT10 promotes osteosarcoma glycolysis and growth by upregulating PFKFB3 via stabilization of EGFR.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32775001","citation_count":26,"is_preprint":false},{"pmid":"25768649","id":"PMC_25768649","title":"Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25768649","citation_count":26,"is_preprint":false},{"pmid":"30361097","id":"PMC_30361097","title":"FAT10 promotes the invasion and migration of breast cancer cell through stabilization of ZEB2.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30361097","citation_count":25,"is_preprint":false},{"pmid":"20888811","id":"PMC_20888811","title":"Increased expression of FAT10 in colon benign, premalignant and malignant epithelial neoplasms.","date":"2010","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20888811","citation_count":25,"is_preprint":false},{"pmid":"26401002","id":"PMC_26401002","title":"The Ubiquitin-like Modifier FAT10 Is Selectively Expressed in Medullary Thymic Epithelial Cells and Modifies T Cell Selection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26401002","citation_count":25,"is_preprint":false},{"pmid":"31729307","id":"PMC_31729307","title":"FAT10: Function and Relationship with Cancer.","date":"2020","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31729307","citation_count":24,"is_preprint":false},{"pmid":"23862649","id":"PMC_23862649","title":"A proteomics strategy for the identification of FAT10-modified sites by mass spectrometry.","date":"2013","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/23862649","citation_count":23,"is_preprint":false},{"pmid":"29620277","id":"PMC_29620277","title":"Ubiquitin‑like protein FAT10 regulates DNA damage repair via modification of proliferating cell nuclear antigen.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29620277","citation_count":22,"is_preprint":false},{"pmid":"34350116","id":"PMC_34350116","title":"Ubiquitin-Like Protein UBD Promotes Cell Proliferation in Colorectal Cancer by Facilitating p53 Degradation.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34350116","citation_count":21,"is_preprint":false},{"pmid":"33253711","id":"PMC_33253711","title":"FAT10 promotes the progression of bladder cancer by upregulating HK2 through the EGFR/AKT pathway.","date":"2020","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33253711","citation_count":21,"is_preprint":false},{"pmid":"26142316","id":"PMC_26142316","title":"Silibinin down-regulates FAT10 and modulate TNF-α/IFN-γ-induced chromosomal instability and apoptosis sensitivity.","date":"2015","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/26142316","citation_count":21,"is_preprint":false},{"pmid":"21757738","id":"PMC_21757738","title":"FAT10 protein binds to polyglutamine proteins and modulates their solubility.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21757738","citation_count":20,"is_preprint":false},{"pmid":"27354218","id":"PMC_27354218","title":"FAT10 Is Critical in Influenza A Virus Replication by Inhibiting Type I IFN.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27354218","citation_count":20,"is_preprint":false},{"pmid":"29208314","id":"PMC_29208314","title":"The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29208314","citation_count":20,"is_preprint":false},{"pmid":"30818228","id":"PMC_30818228","title":"The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30818228","citation_count":19,"is_preprint":false},{"pmid":"33414395","id":"PMC_33414395","title":"FAT10 protects against ischemia-induced ventricular arrhythmia by decreasing Nedd4-2/Nav1.5 complex formation.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33414395","citation_count":19,"is_preprint":false},{"pmid":"21222287","id":"PMC_21222287","title":"FAT10 : Activated by UBA6 and Functioning in Protein Degradation.","date":"2010","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21222287","citation_count":19,"is_preprint":false},{"pmid":"22981937","id":"PMC_22981937","title":"FAT10 knock out mice livers fail to develop Mallory-Denk bodies in the DDC mouse model.","date":"2012","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22981937","citation_count":17,"is_preprint":false},{"pmid":"30009772","id":"PMC_30009772","title":"Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).","date":"2018","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30009772","citation_count":16,"is_preprint":false},{"pmid":"22347407","id":"PMC_22347407","title":"The inherited blindness protein AIPL1 regulates the ubiquitin-like FAT10 pathway.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22347407","citation_count":15,"is_preprint":false},{"pmid":"36361504","id":"PMC_36361504","title":"Recombinant Human Proteoglycan 4 (rhPRG4) Downregulates TNFα-Stimulated NFκB Activity and FAT10 Expression in Human Corneal Epithelial Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36361504","citation_count":15,"is_preprint":false},{"pmid":"23036196","id":"PMC_23036196","title":"Modification of the inflammatory mediator LRRFIP2 by the ubiquitin-like protein FAT10 inhibits its activity during cellular response to LPS.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23036196","citation_count":15,"is_preprint":false},{"pmid":"34571823","id":"PMC_34571823","title":"NUB1 and FAT10 Proteins as Potential Novel Biomarkers in Cancer: A Translational Perspective.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34571823","citation_count":14,"is_preprint":false},{"pmid":"32946796","id":"PMC_32946796","title":"Ubiquitin-like protein FAT10: A potential cardioprotective factor and novel therapeutic target in cancer.","date":"2020","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32946796","citation_count":14,"is_preprint":false},{"pmid":"35986001","id":"PMC_35986001","title":"Crystal structures reveal catalytic and regulatory mechanisms of the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35986001","citation_count":14,"is_preprint":false},{"pmid":"31759325","id":"PMC_31759325","title":"IFNγ potentiates TNFα/TNFR1 signaling to induce FAT10 expression in macrophages.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31759325","citation_count":13,"is_preprint":false},{"pmid":"32586037","id":"PMC_32586037","title":"Regulation of Interferon Induction by the Ubiquitin-Like Modifier FAT10.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32586037","citation_count":12,"is_preprint":false},{"pmid":"27499634","id":"PMC_27499634","title":"FAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancer.","date":"2016","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27499634","citation_count":12,"is_preprint":false},{"pmid":"24452267","id":"PMC_24452267","title":"Diubiquitin (Ubd) is a susceptibility gene for virus-triggered autoimmune diabetes in rats.","date":"2014","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24452267","citation_count":12,"is_preprint":false},{"pmid":"26407761","id":"PMC_26407761","title":"FAT10 suppression stabilizes oxidized proteins in liver cells: Effects of HCV and ethanol.","date":"2015","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26407761","citation_count":12,"is_preprint":false},{"pmid":"37926201","id":"PMC_37926201","title":"The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα.","date":"2023","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/37926201","citation_count":11,"is_preprint":false},{"pmid":"29949944","id":"PMC_29949944","title":"Investigating the Promoter of FAT10 Gene in HCC Patients.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/29949944","citation_count":11,"is_preprint":false},{"pmid":"37057207","id":"PMC_37057207","title":"FAT10 Silencing Prevents Liver Fibrosis through Regulating SIRT1 Expression in Hepatic Stellate Cells.","date":"2023","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37057207","citation_count":11,"is_preprint":false},{"pmid":"36152057","id":"PMC_36152057","title":"Ubiquitin-like protein FAT10 promotes renal fibrosis by stabilizing USP7 to prolong CHK1-mediated G2/M arrest in renal tubular epithelial cells.","date":"2022","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/36152057","citation_count":11,"is_preprint":false},{"pmid":"24440736","id":"PMC_24440736","title":"Recombinant adenovirus encoding FAT10 small interfering RNA inhibits HCC growth in vitro and in vivo.","date":"2014","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24440736","citation_count":11,"is_preprint":false},{"pmid":"30850054","id":"PMC_30850054","title":"Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10.","date":"2019","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/30850054","citation_count":11,"is_preprint":false},{"pmid":"22569823","id":"PMC_22569823","title":"Identification of a novel binding protein of FAT10: eukaryotic translation elongation factor 1A1.","date":"2012","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22569823","citation_count":11,"is_preprint":false},{"pmid":"38824477","id":"PMC_38824477","title":"FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.","date":"2024","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/38824477","citation_count":10,"is_preprint":false},{"pmid":"37328057","id":"PMC_37328057","title":"The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/37328057","citation_count":10,"is_preprint":false},{"pmid":"32630199","id":"PMC_32630199","title":"The Role of FAT10 in Alcoholic Hepatitis Pathogenesis.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/32630199","citation_count":10,"is_preprint":false},{"pmid":"33307094","id":"PMC_33307094","title":"Ubiquitin-like protein FAT10 suppresses SIRT1-mediated autophagy to protect against ischemic myocardial injury.","date":"2020","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33307094","citation_count":10,"is_preprint":false},{"pmid":"38984715","id":"PMC_38984715","title":"Plasticity of the proteasome-targeting signal Fat10 enhances substrate degradation.","date":"2024","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/38984715","citation_count":10,"is_preprint":false},{"pmid":"32817338","id":"PMC_32817338","title":"The ubiquitin-like modifier FAT10 inhibits retinal PDE6 activity and mediates its proteasomal degradation.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32817338","citation_count":10,"is_preprint":false},{"pmid":"35883685","id":"PMC_35883685","title":"IDO1, FAT10, IFI6, and GILT Are Involved in the Antiretroviral Activity of γ-Interferon and IDO1 Restricts Retrovirus Infection by Autophagy Enhancement.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35883685","citation_count":10,"is_preprint":false},{"pmid":"38565741","id":"PMC_38565741","title":"Cytokines-activated nuclear IKKα-FAT10 pathway induces breast cancer tamoxifen-resistance.","date":"2024","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38565741","citation_count":9,"is_preprint":false},{"pmid":"40217121","id":"PMC_40217121","title":"NUB1 traps unfolded FAT10 for ubiquitin-independent degradation by the 26S proteasome.","date":"2025","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/40217121","citation_count":9,"is_preprint":false},{"pmid":"37188463","id":"PMC_37188463","title":"FAT10 and NUB1L cooperate to activate the 26S proteasome.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37188463","citation_count":8,"is_preprint":false},{"pmid":"36778114","id":"PMC_36778114","title":"Ubiquitin like protein FAT10 repressed cardiac fibrosis after myocardial ischemic via mediating degradation of Smad3 dependent on FAT10-proteasome system.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36778114","citation_count":8,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46834,"output_tokens":11283,"usd":0.154873,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22223,"output_tokens":4179,"usd":0.107795,"stage2_stop_reason":"end_turn"},"total_usd":0.262668,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"FAT10 noncovalently associates with MAD2, a spindle-assembly checkpoint protein, as determined by yeast two-hybrid screening and immunoprecipitation studies.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and yeast two-hybrid, single lab, two orthogonal methods\",\n      \"pmids\": [\"10200259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FAT10 forms covalent conjugates with cellular proteins via its C-terminal diglycine motif (isopeptide bond), and expression of wild-type but not diglycine-mutant FAT10 induces caspase-dependent apoptosis in mouse fibroblasts.\",\n      \"method\": \"Tetracycline-repressible expression system, annexin V staining, DNA fragmentation assay, diglycine mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional mutagenesis with multiple apoptosis readouts, single lab\",\n      \"pmids\": [\"11445583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NUB1L (NEDD8 ultimate buster-1L) interacts noncovalently with FAT10 more strongly than with NEDD8, and NUB1L coexpression accelerates FAT10 degradation approximately 8-fold, likely by linking FAT10 to the proteasome via RPN10.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, GST pull-down, cycloheximide chase degradation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, GST pulldown, functional degradation assay, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"14757770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FAT10 and its conjugates are rapidly degraded by the proteasome in a ubiquitin-independent manner; mutation of all lysines on FAT10 or expression in ubiquitylation-deficient cells does not impair FAT10 degradation; N-terminal fusion of FAT10 to long-lived proteins accelerates their degradation as potently as ubiquitin fusion.\",\n      \"method\": \"Cycloheximide chase, proteasome inhibitor treatment, ubiquitylation-deficient cell lines, FAT10-GFP fusion protein degradation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including mutant cells and fusion protein assays, rigorous controls\",\n      \"pmids\": [\"15831455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FAT10 overexpression reduces kinetochore localization of MAD2 during prometaphase, abbreviates mitotic phase, and causes increased chromosomal instability (multinucleation, variable chromosome number) in cells.\",\n      \"method\": \"Immunofluorescence, flow cytometry, double-thymidine synchronization, nocodazole treatment, chromosome counting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct imaging of kinetochore localization with functional chromosome instability readout, single lab\",\n      \"pmids\": [\"16495226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"p53 negatively regulates FAT10 expression by binding to a p53-binding site in the FAT10 promoter (5'UTR region), as shown by promoter-luciferase assays and chromatin immunoprecipitation.\",\n      \"method\": \"Promoter-luciferase assay, siRNA knockdown, ChIP, p53 transfection into p53-null cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and functional luciferase assays, multiple approaches, single lab\",\n      \"pmids\": [\"16501612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"UBA6 (E1-L2) is the E1-activating enzyme for FAT10; it forms a thioester with FAT10 in vitro requiring UBA6's active-site cysteine and FAT10's C-terminal diglycine motif; RNAi silencing of UBA6 blocks FAT10 conjugate formation in cells.\",\n      \"method\": \"In vitro thioester formation assay, active-site cysteine mutagenesis, RNAi knockdown, endogenous co-immunoprecipitation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis plus cellular RNAi validation, multiple orthogonal methods\",\n      \"pmids\": [\"17889673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FAT10 interacts with HDAC6 via the HDAC6 BUZ domain and first catalytic domain (catalytic activity not required); under proteasome impairment, FAT10 and FAT10 conjugates localize to aggresomes in a microtubule-dependent manner, and aggresome formation is reduced in HDAC6-deficient fibroblasts.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, live-cell imaging, microtubule depolymerization, HDAC6-deficient fibroblasts\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional genetic knockout, live-cell localization, multiple orthogonal methods\",\n      \"pmids\": [\"19033385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FAT10-mediated degradation of FAT10-DHFR by purified 26S proteasome in vitro is ubiquitin-independent but strictly requires NUB1L; NUB1L knockdown attenuates FAT10-DHFR degradation in intact cells.\",\n      \"method\": \"In vitro proteasome degradation assay with purified components, siRNA knockdown, cycloheximide chase\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified 26S proteasome, confirmed in cells by knockdown, rigorous controls\",\n      \"pmids\": [\"19166848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FAT10 deficiency in renal tubular epithelial cells impairs TNF-α-induced IκBα degradation and p65 nuclear translocation, and reduces LMP2 expression; re-expression of FAT10 restores NF-κB activation, and LMP2 transfection rescues IκBα degradation in FAT10-deficient cells.\",\n      \"method\": \"FAT10-/- mouse-derived cells, lentiviral transduction, Western blot, nuclear fractionation, NF-κB reporter assay\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout cells with rescue experiment, multiple pathway readouts, single lab\",\n      \"pmids\": [\"19959714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"USE1 (UBA6-specific E2 enzyme) is both the first E2 conjugating enzyme and the first identified substrate in the FAT10 pathway; activated FAT10 is transferred from UBA6 onto USE1 in vitro; USE1 auto-FAT10ylates itself in cis but not in trans; siRNA-mediated USE1 knockdown strongly reduces FAT10 conjugate formation.\",\n      \"method\": \"In vitro FAT10 transfer assay, co-immunoprecipitation, siRNA knockdown, cis vs trans auto-FAT10ylation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, cellular validation by knockdown, mechanistic dissection of cis vs trans activity, multiple methods\",\n      \"pmids\": [\"20975683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNF-α induces FAT10 expression through TNFR1 and NF-κB, and FAT10 mediates TNF-α-induced abbreviated mitotic phase, reduction of MAD2 kinetochore localization, and chromosomal instability; shRNA against FAT10 reverses these effects.\",\n      \"method\": \"shRNA knockdown, flow cytometry, immunofluorescence, chromosome counting, TNF-α treatment with receptor blocking\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA rescue experiments with specific pathway readouts, single lab, multiple methods\",\n      \"pmids\": [\"22025632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FAT10 is covalently attached (via C-terminal glycine) to huntingtin and other polyglutamine proteins; FAT10 preferentially binds huntingtin with short polyQ chains; FAT10 knockdown enhances aggregation of ataxin-1, ataxin-3, and DRPLA proteins.\",\n      \"method\": \"Co-immunoprecipitation, FAT10 knockdown, aggregation assay in Huntington disease cell model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with knockdown validation, multiple polyQ substrates tested, single lab\",\n      \"pmids\": [\"21757738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FAT10 degradation requires ubiquitination: degradation is inhibited in cells expressing a non-polymerizable ubiquitin mutant and in cells with a thermolabile ubiquitin-activating E1 enzyme; FAT10 as a degradation signal for stable proteins also requires ubiquitination for proteasomal targeting.\",\n      \"method\": \"Ubiquitin mutant expression, thermolabile E1 mutant cell line, cycloheximide chase\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent genetic approaches showing ubiquitin dependence, single lab; note this contradicts Hipp et al. 2005 ubiquitin-independence finding\",\n      \"pmids\": [\"22072791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FAT10 and NUB1L bind to the VWA domain of 26S proteasome subunit Rpn10 (hRpn10/S5a) to enable FAT10-mediated proteolysis; NUB1L additionally binds Rpn1; depletion of hRpn10 causes accumulation of FAT10-conjugates in human cells; human Rpn10 with VWA domain alone functionally reconstitutes Rpn10-deficient yeast for FAT10 degradation.\",\n      \"method\": \"Co-immunoprecipitation, yeast complementation, siRNA knockdown, domain deletion mapping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including yeast reconstitution, domain mapping, human cell depletion, cross-species validation\",\n      \"pmids\": [\"22434192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Endogenous FAT10 conjugates include the autophagy adaptor p62/SQSTM1 as a covalent mono-FAT10ylated substrate at multiple lysines; FAT10 colocalizes with p62 in p62 bodies; FAT10ylation of p62 leads to its proteasomal degradation; mass spectrometry identified 569 FAT10-interacting proteins including HDAC6 and UBA6.\",\n      \"method\": \"Immunopurification of endogenous FAT10 conjugates, mass spectrometry, co-immunoprecipitation, colocalization imaging, proteasome inhibitor treatment\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mass spectrometry-based substrate identification with functional validation of p62 FAT10ylation and degradation, multiple orthogonal methods\",\n      \"pmids\": [\"22797925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FAT10 modification promotes MHC class I antigen presentation of viral pp65 antigen; this presentation partially relies on Rpn10 and is supported by NUB1 but is not influenced by immunoproteasomes or PA28, distinguishing FAT10 from ubiquitin-dependent presentation.\",\n      \"method\": \"Antigen presentation assays, proteasome inhibitor treatment, siRNA knockdown of pathway components\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional antigen presentation assays with mechanistic knockdowns, single lab\",\n      \"pmids\": [\"22349260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AIPL1 (LCA blindness protein) binds noncovalently to free FAT10 and FAT10ylated proteins, forms a ternary complex with FAT10 and NUB1, and antagonizes NUB1-mediated FAT10-DHFR degradation; AIPL1 also co-immunoprecipitates UBA6.\",\n      \"method\": \"Co-immunoprecipitation, degradation assay, AIPL1 mutant analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with functional degradation assay and mutant analysis, single lab\",\n      \"pmids\": [\"22347407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FAT10 covalently modifies LRRFIP2 at two distinct sites; FATylation of LRRFIP2 translocates it to the cellular insoluble fraction, preventing its membrane recruitment with MYD88 and thereby inhibiting TLR4-mediated NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, NF-κB reporter assay, LPS stimulation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — covalent modification confirmed with functional pathway readout, single lab\",\n      \"pmids\": [\"23036196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Uba6 activates FAT10 through a three-step mechanism similar to Uba1 (adenylation and thioester formation); FAT10 binds Uba6 with higher affinity than ubiquitin but shows lower catalytic activity in E1-E2 transthiolation; FAT10 forms a ternary complex with Uba6 together with ubiquitin.\",\n      \"method\": \"Biochemical kinetics, ATP-PPi exchange assay, E1-E2 transthiolation assay, mechanism-based E1 inhibitor studies, biophysical binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vitro enzymatic characterization with pre-steady state kinetics and inhibitor studies\",\n      \"pmids\": [\"22427669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The MAD2-binding interface of FAT10 is located on its first ubiquitin-like domain; NMR structure of this domain was determined; mutation of specific MAD2-binding residues abrogates FAT10-MAD2 interaction without disrupting FAT10's other interactions; disruption of FAT10-MAD2 binding dramatically reduces FAT10-mediated tumor growth, aneuploidy, proliferation, migration, invasion, and apoptosis resistance.\",\n      \"method\": \"NMR structure determination, site-directed mutagenesis, co-immunoprecipitation, in vitro and in vivo tumor assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure plus mutagenesis plus functional validation in vitro and in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"25422469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FAT10 directly binds β-catenin, preventing its ubiquitination and degradation, thereby activating the β-catenin/TCF4 pathway and upregulating HOXB9 expression to promote HCC invasion and metastasis.\",\n      \"method\": \"Co-immunoprecipitation, RNAi knockdown, rescue experiments with HOXB9 overexpression, in vitro invasion assays, in vivo mouse models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with functional rescue experiments, single lab, in vitro and in vivo validation\",\n      \"pmids\": [\"25056121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FAT10 decorates cytosolic Salmonella Typhimurium in human cells; FAT10-decorated bacteria colocalize with ubiquitin, p62, NDP52, and LC3B; FAT10 colocalizes with p62-positive microdomains; FAT10-deficient NRAMP1-transgenic mice show higher susceptibility to oral S. Typhimurium infection.\",\n      \"method\": \"Immunofluorescence colocalization, siRNA knockdown, FAT10-deficient mouse infection model\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct imaging with genetic mouse model validation, single lab\",\n      \"pmids\": [\"25271057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"UBE1 (ubiquitin E1) is a substrate of FAT10; FAT10ylation of UBE1 depends on the diglycine motif of FAT10 and the UBA6/USE1 conjugation pathway; FAT10ylated UBE1 undergoes proteasomal degradation; UBE1 does not act as a second E1 for FAT10.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, siRNA knockdown of UBA6/USE1, proteasome inhibitor treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous conjugate confirmed with pathway-specific knockdowns and proteasome inhibition, single lab\",\n      \"pmids\": [\"25768649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of USE1 (UBE2Z) reveals domain organization; specificity of FAT10 conjugation toward UBA6 and USE1 lies within the C-terminal CYCI tetrapeptide of FAT10; this motif slows the transfer rate of FAT10 from UBA6 onto USE1.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, biochemical transfer assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis plus biochemical assays in single study\",\n      \"pmids\": [\"26555268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FAT10 is selectively expressed in medullary thymic epithelial cells (mTECs) and alters the repertoire of MHC class I-presented peptides and thymic negative selection; FAT10-deficient mice show altered T cell repertoire and impaired negative selection in TCR-transgenic models.\",\n      \"method\": \"FAT10-/- mice, TCR Vβ-segment screening, MHC class I peptide elution, TCR-transgenic mouse analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with MHC peptide repertoire analysis and functional T cell selection readouts, single lab\",\n      \"pmids\": [\"26401002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FAT10 competes with ubiquitin for binding to the same lysines on eEF1A1; FAT10 overexpression decreases ubiquitin-eEF1A1 conjugates and increases FAT10-eEF1A1 conjugates, stabilizing eEF1A1 and promoting cancer cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, lysine mutants, Western blot, proliferation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — competition assay with lysine mutants and dual conjugate detection, single lab\",\n      \"pmids\": [\"27312528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FAT10 noncovalently associates with the 2CARD domain of RIG-I; FAT10 inhibits viral RNA-induced IRF3 and NF-κB activation by modulating RIG-I protein solubility; FAT10 is recruited to the RIG-I-TRIM25 complex where it is stabilized by TRIM25; FAT10 sequesters active RIG-I away from mitochondria and inhibits antiviral stress granule formation.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, luciferase reporter assay, fractionation/solubility assay, immunofluorescence colocalization\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain specificity, multiple functional readouts, single lab\",\n      \"pmids\": [\"26996158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FAT10 directly binds to Nav1.5 at lysine residues in its C-terminal fragments and prevents Nedd4-2 (ubiquitin E3 ligase) binding, stabilizing Nav1.5 membrane expression; cardiac-specific Fat10 knockout causes reduced peak Na+ current, increased late Na+ current, and ventricular arrhythmia after myocardial infarction.\",\n      \"method\": \"Cardiac-specific Cre-lox knockout, patch-clamp electrophysiology, co-immunoprecipitation, immunofluorescence\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic cardiac-specific KO with electrophysiology, Co-IP mapping interaction site, multiple orthogonal readouts\",\n      \"pmids\": [\"33414395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"High-resolution NMR/crystal structures of the two individual ubiquitin-like domains (UBDs) of FAT10 show typical ubiquitin-fold but entirely different surface properties from each other and from ubiquitin; deletion of the flexible linker abrogates FAT10 conjugation; mutation of the linker blocks USE1 auto-FAT10ylation but not bulk conjugate formation; FAT10-mediated degradation is independent of VCP/p97 when FAT10's unstructured N-terminal heptapeptide is present; intrinsic instability of FAT10 enables rapid co-degradation of FAT10 and its substrates without de-conjugation.\",\n      \"method\": \"NMR structure, domain deletion and mutagenesis, in vitro degradation assays, VCP/p97 inhibition\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution structure with mutagenesis and functional in vitro assays, multiple orthogonal methods\",\n      \"pmids\": [\"30127417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"UBD/FAT10 expression inversely correlates with APOL1 G1/G2 variant-mediated cell toxicity; disease-associated APOL1 alleles increase UBD mRNA but decrease UBD protein; UBD appears to mitigate APOL1-mediated toxicity by targeting APOL1 for proteasomal degradation.\",\n      \"method\": \"Admixture mapping, cell-based expression assays, Western blot, cell toxicity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cell-based assays with correlation data, no direct biochemical demonstration of FAT10-APOL1 conjugation, single study\",\n      \"pmids\": [\"29531077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FAT10 directly binds to and impedes the SUMO E1 activating enzyme AOS1/UBA2, competing with SUMO for activation and thioester formation in vitro; FAT10 overexpression downregulates SUMO conjugation and SUMO-dependent PML body formation in cells; activation of FAT10 by AOS1/UBA2 does not lead to covalent FAT10 conjugation to substrates.\",\n      \"method\": \"In vitro thioester formation assay, competition assay, Western blot, immunofluorescence of PML bodies\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution showing direct competition with mechanistic dissection, cellular validation with functional readout\",\n      \"pmids\": [\"31575873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZNF598 delivers FAT10 to RIG-I, resulting in inhibition of RIG-I polyubiquitination required for downstream IFN signaling; ZNF598 ubiquitin ligase activity is dispensable for this suppression; ZNF598-mediated suppression is abolished by FAT10 knockout.\",\n      \"method\": \"Co-immunoprecipitation, FAT10 knockout cells, RIG-I ubiquitination assay, IFN reporter assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout validation with mechanism of polyubiquitination inhibition, single lab\",\n      \"pmids\": [\"31433974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FAT10 noncovalently interacts with OTUB1 and stimulates its deubiquitylase activity toward Lys-48-linked diubiquitin; covalent FAT10ylation of OTUB1 leads to its proteasomal degradation; FAT10-OTUB1 interaction also strengthens OTUB1's noncatalytic inhibition of Lys-63 polyubiquitylation of TRAF3; FAT10 increases OTUB1 interaction with UbcH5B.\",\n      \"method\": \"Co-immunoprecipitation, in vitro DUB activity assay, co-immunoprecipitation with E2 enzyme, proteasome inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro enzymatic assays with cellular validation, single lab, multiple functional readouts\",\n      \"pmids\": [\"30718280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FAT10 directly interacts with PPARα in hepatocytes; FAT10 silencing increases PPARα target gene expression and promotes fatty acid oxidation; FAT10 overexpression in vivo inhibits PPARα lipid regulatory activity in response to fasting and agonist treatment.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, in vivo hepatocyte FAT10 overexpression, fatty acid oxidation assay\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with in vivo functional validation, single lab\",\n      \"pmids\": [\"37926201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Parkin is an E3 ligase for FAT10; FAT10 becomes conjugated to Parkin and targets it for proteasomal degradation; Parkin binds the FAT10 E2 enzyme USE1 and auto-FAT10ylates itself; Parkin facilitates FAT10ylation of Mitofusin2 in vitro and in cells; on mitochondrial depolarization, FAT10ylation of Parkin inhibits its ubiquitin-ligase activity and impairs mitophagy.\",\n      \"method\": \"In vitro FAT10ylation assay, co-immunoprecipitation, proteasome inhibitor treatment, mitochondrial depolarization assay, dopaminergic cell death assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro reconstitution of E3 ligase activity plus cellular validation of mitophagy impairment, multiple orthogonal methods\",\n      \"pmids\": [\"33730565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UBD/FAT10 interacts with p53 in colorectal cancer cells, promotes its proteasomal degradation, and shortens p53 half-life, leading to decreased p21 and increased cyclins/CDKs and cell proliferation; in vivo tumor growth driven by UBD depends on p53 decrease.\",\n      \"method\": \"Co-immunoprecipitation, cycloheximide chase, proteasome inhibitor treatment, xenograft mouse model\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, half-life assay, in vivo rescue experiment, single lab\",\n      \"pmids\": [\"34350116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structures of human Uba6 in complex with ubiquitin reveal two conformations: open (adenylation-active) and closed (thioester-active); an allosteric inositol hexakisphosphate (InsP6) binding site on Uba6 inhibits its activity by altering open-closed conformational interconversion; these structures provide the molecular basis for FAT10 and ubiquitin activation.\",\n      \"method\": \"X-ray crystallography, biochemical activity assays, biophysical binding assays, site-directed mutagenesis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures with biochemical and biophysical validation of allosteric mechanism\",\n      \"pmids\": [\"35986001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FAT10 directly binds FOXM1 and stabilizes it by competing with ubiquitin for binding to FOXM1, inhibiting ubiquitination-mediated FOXM1 degradation, thereby promoting EMT and gemcitabine resistance in pancreatic cancer.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, rescue experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with competition-based ubiquitination assay and functional rescue, single lab\",\n      \"pmids\": [\"35614040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FAT10 directly binds Smad3 at K378 via its C-terminal glycine residues and mediates Smad3 degradation through the FAT10-proteasome system independently of ubiquitin; FAT10-/- mice show excessive cardiac fibrosis after myocardial infarction; FAT10 restoration suppresses fibrosis in a Smad3-dependent manner.\",\n      \"method\": \"IP-mass spectrometry, co-immunoprecipitation, FAT10-/- mouse model, in vivo rescue, in vitro fibroblast assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IP-MS substrate identification with genetic mouse model validation and site-specific binding data, single lab\",\n      \"pmids\": [\"36778114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FAT10 and NUB1L cooperate to activate 26S proteasome gate opening in a ubiquitin- and USP14-independent manner; FAT10 binding to UBA domains of NUB1L interferes with NUB1L dimerization, increasing NUB1L affinity for RPN1 and thereby activating proteasomal peptidolytic activities.\",\n      \"method\": \"In vitro proteasome activity assay, co-immunoprecipitation, domain binding assays\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assays with mechanistic dissection, single lab\",\n      \"pmids\": [\"37188463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FAT10 structural plasticity (lower thermodynamic stability, faster mechanical unfolding, absent long-range salt bridges, partially unstructured regions) is critical for its function as a proteasomal degradation tag; Fat10's unfolding destabilizes conjugated substrates creating partially unstructured regions that enhance proteasomal engagement and degradation rate.\",\n      \"method\": \"NMR relaxation analysis, hydrogen-deuterium exchange, temperature-dependent chemical shift, force spectroscopy (mechanical unfolding), in vitro degradation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple structural and biophysical methods with in vitro degradation validation, rigorous mechanistic dissection\",\n      \"pmids\": [\"38984715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NUB1 uses intrinsic instability of FAT10 to trap its N-terminal ubiquitin-like domain in an unfolded state and deliver it to the 26S proteasome for engagement; cryo-EM structures visualize the NUB1 complex bound to proteasomal Rpn1 during FAT10 delivery; this delivery is ubiquitin-independent and p97-independent; NUB1 binding activates NUB1 for proteasomal docking.\",\n      \"method\": \"In vitro reconstitution, hydrogen-deuterium exchange, cryo-EM, structural modeling, site-directed mutagenesis\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure plus in vitro reconstitution plus HDX and mutagenesis, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"40217121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FAT10 inhibits PDE6 cGMP hydrolyzing activity by noncovalently interacting with PDE6 GAFa and catalytic domains; FAT10 also covalently conjugates to rod PDE6 and targets it for proteasomal degradation; AIPL1 stabilizes both FAT10 monomer and the PDE6-FAT10 conjugate.\",\n      \"method\": \"In vitro PDE6 activity assay, co-immunoprecipitation, proteasome inhibitor treatment, domain interaction mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro enzymatic assay with cellular validation, single lab, multiple readouts\",\n      \"pmids\": [\"32817338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FAT10 directly binds to EGFR and inhibits its ubiquitination and degradation, stabilizing EGFR expression; this stabilization upregulates PFKFB3 via the EGFR/AKT pathway, promoting glycolysis and osteosarcoma growth.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, in vitro and in vivo proliferation assays\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and ubiquitination assay, indirect pathway linkage, single lab\",\n      \"pmids\": [\"32775001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FAT10 directly interacts with and stabilizes the deubiquitylating enzyme USP7; FAT10-USP7 interaction mediates CHK1 upregulation, prolonging CHK1-mediated G2/M arrest in renal tubular epithelial cells exposed to hypoxia, promoting pro-fibrotic cytokine production.\",\n      \"method\": \"Co-immunoprecipitation, FAT10-/- mouse-derived cells, Western blot, cell cycle analysis\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP with genetic cell model, indirect pathway linkage, single lab\",\n      \"pmids\": [\"36152057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FAT10 suppresses autophagy by competing with SUMO1 at the K734 modification site of SIRT1, reducing SIRT1 nuclear translocation and activity via its C-terminal glycine residues; this reduces LC3 deacetylation and suppresses autophagosome formation, protecting the heart from ischemic injury.\",\n      \"method\": \"Co-immunoprecipitation, FAT10-knockout rat model, SIRT1 SUMOylation assay, autophagy flux assay, in vivo/in vitro ischemia models\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with mechanistic competition assay and functional autophagy readout, single lab\",\n      \"pmids\": [\"33307094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FAT10 promotes NF-κB activation, which upregulates CXCR4 and CXCR7 chemokine receptors; siRNA depletion of CXCR7 and CXCR4 attenuates invasion of FAT10-overexpressing cells, establishing the NF-κB-CXCR4/7 pathway as the mechanism for FAT10-induced malignant transformation.\",\n      \"method\": \"NF-κB reporter assay, siRNA knockdown, invasion assays, anchorage-independent growth, in vivo tumor formation\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection with siRNA rescue, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"24325913\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FAT10 (UBD) is a cytokine-inducible (IFNγ+TNFα) ubiquitin-like modifier encoded in the MHC class I locus that is activated by the E1 enzyme UBA6 via adenylation and thioester formation, transferred to the dedicated E2 enzyme USE1 (which auto-FAT10ylates itself in cis), and covalently conjugated to hundreds of substrate proteins via an isopeptide bond to internal lysines, targeting them for ubiquitin-independent but NUB1L-dependent 26S proteasomal degradation through docking of FAT10/NUB1L to the VWA domain of Rpn10 and Rpn1; FAT10's intrinsic structural plasticity and low thermodynamic stability are critical for enabling the proteasomal engagement that co-degrades FAT10 and substrate without de-conjugation, while NUB1L traps FAT10's unfolded N-terminal domain to deliver it to the proteasome; noncovalently, FAT10 interacts with MAD2 (disrupting kinetochore localization and causing chromosomal instability), RIG-I (sequestering it from its signaling platform to suppress antiviral signaling), OTUB1 (stimulating its deubiquitylase activity), β-catenin and multiple protein substrates (competing with ubiquitin to stabilize them), HDAC6 (enabling aggresome transport when proteasome is impaired), and the SUMO E1 enzyme AOS1/UBA2 (inhibiting SUMO activation and conjugation); Parkin has been identified as an E3 ligase for FAT10 that mediates auto-FAT10ylation and Mitofusin2 FAT10ylation, while FAT10ylation of Parkin in turn inhibits mitophagy; FAT10 expression is transcriptionally regulated by NF-κB, STAT3, and IFNγ-responsive elements, and is negatively regulated by p53.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FAT10 (UBD) is a ubiquitin-like protein modifier that conjugates to target proteins through its C-terminal diglycine motif and directs them, together with itself, to the 26S proteasome for degradation [#1, #3]. Activation proceeds through a dedicated enzymatic cascade: the E1 enzyme UBA6 activates FAT10 by adenylation and thioester formation requiring its active-site cysteine and FAT10's diglycine motif [#6, #19], and transfers it to the E2 enzyme USE1, which auto-FAT10ylates itself in cis and is the first identified substrate of the pathway [#10]; specificity for UBA6/USE1 is encoded in FAT10's C-terminal CYCI tetrapeptide [#24], and Parkin acts as an E3 ligase that drives auto-FAT10ylation and modification of Mitofusin2 [#35]. FAT10-mediated proteolysis is ubiquitin-independent and instead requires NUB1L, which docks FAT10 to the proteasome via the VWA domain of Rpn10 and via Rpn1 [#2, #8, #14]; NUB1 exploits FAT10's intrinsic structural plasticity and low thermodynamic stability to trap its unfolded N-terminal domain and deliver it to the proteasome, enabling co-degradation of FAT10 and substrate without de-conjugation [#29, #41, #42]. Beyond covalent conjugation, FAT10 acts noncovalently to stabilize or sequester binding partners: it binds the SUMO E1 AOS1/UBA2 to inhibit SUMO activation [#31], the spindle-checkpoint protein MAD2 to displace it from kinetochores and drive chromosomal instability [#4, #20], and competes with ubiquitin on shared lysines of substrates such as \\u03b2-catenin to stabilize them and promote oncogenic signaling [#21, #26]. FAT10 is induced by TNF-\\u03b1/NF-\\u03baB signaling and negatively regulated by p53 [#5, #11], and functions in immune regulation, antiviral signaling through RIG-I suppression [#27, #32], antigen presentation and thymic selection [#16, #25], and mitochondrial quality control by inhibiting Parkin-dependent mitophagy [#35].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the first FAT10 binding partner, linking the protein to mitotic checkpoint control before its enzymology was understood.\",\n      \"evidence\": \"Yeast two-hybrid screen and reciprocal co-IP identifying MAD2 association\",\n      \"pmids\": [\"10200259\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction interface not mapped at this stage\", \"Functional consequence for the checkpoint not yet demonstrated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated that FAT10 is a covalent protein modifier whose conjugation depends on its C-terminal diglycine and has cellular consequences.\",\n      \"evidence\": \"Tetracycline-repressible expression with diglycine mutant and apoptosis readouts in mouse fibroblasts\",\n      \"pmids\": [\"11445583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conjugating enzymes unidentified\", \"Substrate identities unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined FAT10 as a proteasomal degradation signal acting independently of ubiquitin, distinguishing it from canonical ubiquitin-mediated turnover.\",\n      \"evidence\": \"Cycloheximide chase, proteasome inhibition, lysine-mutant FAT10, ubiquitylation-deficient cells and FAT10-GFP fusion assays\",\n      \"pmids\": [\"15831455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of proteasome docking not yet resolved\", \"A 2011 study (#13) reported ubiquitin-dependence, leaving the requirement contested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified UBA6 as the activating E1 enzyme, establishing the entry point of the FAT10 conjugation cascade.\",\n      \"evidence\": \"In vitro thioester assay with active-site cysteine mutagenesis plus cellular RNAi\",\n      \"pmids\": [\"17889673\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream E2 not yet identified at this point\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified USE1 as the dedicated E2 and first pathway substrate, completing the E1-E2 transfer chain and revealing cis auto-modification.\",\n      \"evidence\": \"In vitro FAT10 transfer assay, cis vs trans auto-FAT10ylation, siRNA knockdown\",\n      \"pmids\": [\"20975683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligases for general substrates not defined\", \"Mechanism of cis-only auto-modification unexplained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established NUB1L as the strict cofactor coupling FAT10 to the proteasome, explaining ubiquitin-independent delivery.\",\n      \"evidence\": \"In vitro degradation of FAT10-DHFR by purified 26S proteasome and cellular NUB1L knockdown\",\n      \"pmids\": [\"19166848\", \"14757770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NUB1L-FAT10-proteasome engagement not yet resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapped the proteasomal docking site, showing FAT10/NUB1L engage the Rpn10 VWA domain and Rpn1, providing the receptor for ubiquitin-independent delivery.\",\n      \"evidence\": \"Co-IP, domain mapping, siRNA depletion and yeast complementation with VWA-only Rpn10\",\n      \"pmids\": [\"22434192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the engaged substrate is unfolded at the proteasome not addressed\", \"Stoichiometry of the delivery complex unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the endogenous FAT10 substrate landscape by proteomics, anchoring FAT10 to autophagy and confirming hundreds of conjugates.\",\n      \"evidence\": \"Immunopurification of endogenous conjugates with mass spectrometry identifying 569 interactors and validating p62/SQSTM1 modification\",\n      \"pmids\": [\"22797925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Site-specific modification stoichiometry on most substrates unknown\", \"Functional consequence beyond p62 degradation not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Localized the MAD2-binding interface to FAT10's first UBL domain and showed its disruption abolishes pro-tumorigenic activity, separating a noncovalent function from conjugation.\",\n      \"evidence\": \"NMR structure, residue-specific mutagenesis, and in vitro/in vivo tumor assays\",\n      \"pmids\": [\"25422469\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How displaced MAD2 fails to localize to kinetochores mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that FAT10 stabilizes oncogenic substrates by directly competing with ubiquitin for shared lysines.\",\n      \"evidence\": \"Co-IP, lysine-mutant analysis and dual conjugate detection on eEF1A1, alongside \\u03b2-catenin stabilization (#21)\",\n      \"pmids\": [\"27312528\", \"25056121\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of competition versus active conjugation across substrates not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a noncovalent regulatory function: FAT10 inhibits SUMO activation by directly impeding the SUMO E1, expanding its role beyond degradation.\",\n      \"evidence\": \"In vitro thioester competition assay and cellular PML-body and SUMO-conjugation readouts\",\n      \"pmids\": [\"31575873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequences of SUMO suppression not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified Parkin as a FAT10 E3 ligase and a reciprocal regulatory loop in which FAT10ylation of Parkin inhibits mitophagy.\",\n      \"evidence\": \"In vitro FAT10ylation reconstitution, co-IP, and mitochondrial depolarization assays\",\n      \"pmids\": [\"33730565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other E3 ligases serve different substrate classes unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Explained why FAT10 functions as a degron: its intrinsic structural instability and rapid unfolding promote proteasomal engagement and destabilize attached substrates.\",\n      \"evidence\": \"NMR relaxation, hydrogen-deuterium exchange, force spectroscopy and in vitro degradation assays\",\n      \"pmids\": [\"38984715\", \"30127417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Behavior on physiological multi-domain substrates in vivo not fully tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Visualized the delivery mechanism, showing NUB1 traps FAT10's unfolded N-terminal UBL and docks it to proteasomal Rpn1 independently of ubiquitin and p97.\",\n      \"evidence\": \"Cryo-EM, in vitro reconstitution, HDX and mutagenesis of the NUB1-proteasome complex\",\n      \"pmids\": [\"40217121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hand-off from NUB1 to the ATPase translocation channel not resolved\", \"Regulation of NUB1 activation in cells unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FAT10 substrate selection is achieved for its hundreds of conjugates, and what E3 ligases beyond Parkin direct specific FAT10ylation, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No general substrate-recognition code defined\", \"Few E3 ligases identified\", \"Balance between covalent conjugation and noncovalent sequestration per substrate unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0031386\", \"supporting_discovery_ids\": [1, 3, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 20, 27, 31, 33]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [27, 31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 7, 15]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9, 46]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 8, 14, 42]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [16, 25, 27, 32]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 20]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [35, 46]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"UBA6\", \"USE1\", \"NUB1L\", \"MAD2\", \"RPN10\", \"HDAC6\", \"OTUB1\", \"AOS1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}